1. Home
  2. GRAF vs LUNG Comparison

GRAF vs LUNG Comparison

Compare GRAF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRAF
  • LUNG
  • Stock Information
  • Founded
  • GRAF 2021
  • LUNG 1995
  • Country
  • GRAF United States
  • LUNG United States
  • Employees
  • GRAF N/A
  • LUNG N/A
  • Industry
  • GRAF
  • LUNG Industrial Specialties
  • Sector
  • GRAF
  • LUNG Health Care
  • Exchange
  • GRAF NYSE
  • LUNG Nasdaq
  • Market Cap
  • GRAF 291.2M
  • LUNG 256.3M
  • IPO Year
  • GRAF 2024
  • LUNG 2020
  • Fundamental
  • Price
  • GRAF $10.16
  • LUNG $8.96
  • Analyst Decision
  • GRAF
  • LUNG Buy
  • Analyst Count
  • GRAF 0
  • LUNG 6
  • Target Price
  • GRAF N/A
  • LUNG $11.92
  • AVG Volume (30 Days)
  • GRAF 4.8K
  • LUNG 392.8K
  • Earning Date
  • GRAF 01-01-0001
  • LUNG 02-19-2025
  • Dividend Yield
  • GRAF N/A
  • LUNG N/A
  • EPS Growth
  • GRAF N/A
  • LUNG N/A
  • EPS
  • GRAF 0.25
  • LUNG N/A
  • Revenue
  • GRAF N/A
  • LUNG $83,789,000.00
  • Revenue This Year
  • GRAF N/A
  • LUNG $22.26
  • Revenue Next Year
  • GRAF N/A
  • LUNG $18.72
  • P/E Ratio
  • GRAF $40.96
  • LUNG N/A
  • Revenue Growth
  • GRAF N/A
  • LUNG 22.01
  • 52 Week Low
  • GRAF $9.03
  • LUNG $5.46
  • 52 Week High
  • GRAF $11.02
  • LUNG $11.73
  • Technical
  • Relative Strength Index (RSI)
  • GRAF N/A
  • LUNG 75.17
  • Support Level
  • GRAF N/A
  • LUNG $6.50
  • Resistance Level
  • GRAF N/A
  • LUNG $9.37
  • Average True Range (ATR)
  • GRAF 0.00
  • LUNG 0.54
  • MACD
  • GRAF 0.00
  • LUNG 0.26
  • Stochastic Oscillator
  • GRAF 0.00
  • LUNG 89.21

About GRAF GRAF GLOBAL CORP

Graf Global Corp is a blank check company.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: